NASDAQ · PHAR
Healthcare · Biotechnology
$11.85
Up+$0.17 (+1.46%)
Updated Aug 22, 2026, 3:39 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
PHAR closed at $11.85 after 21 trading sessions, down 6.06% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $11.76 | $11.97 | $11.73 | $11.85 | 11.01K |
| Aug 20, 2026 | $11.84 | $12.0335 | $11.68 | $11.68 | 17.98K |
| Aug 19, 2026 | $11.89 | $12.05 | $11.675 | $11.85 | 17.23K |
| Aug 18, 2026 | $11.65 | $11.91 | $11.50 | $11.91 | 22.01K |
| Aug 17, 2026 | $11.72 | $12.1215 | $11.72 | $11.79 | 17.28K |
| Aug 14, 2026 | $11.92 | $12.5083 | $11.6672 | $11.72 | 20.71K |
| Aug 13, 2026 | $12.06 | $13.32 | $11.80 | $12.35 | 32.81K |
| Aug 12, 2026 | $11.81 | $12.1302 | $11.64 | $11.83 | 38.28K |
| Aug 11, 2026 | $11.46 | $12.34 | $11.31 | $12.23 | 89.78K |
| Aug 10, 2026 | $10.82 | $11.7158 | $10.5377 | $11.35 | 62.6K |
| Aug 7, 2026 | $11.08 | $11.15 | $10.89 | $10.95 | 6.39K |
| Aug 6, 2026 | $10.76 | $10.99 | $10.715 | $10.85 | 3.74K |
| Aug 5, 2026 | $10.66 | $10.8492 | $10.54 | $10.675 | 5.28K |
| Aug 4, 2026 | $10.40 | $10.5505 | $10.01 | $10.26 | 10.5K |
| Aug 3, 2026 | $10.13 | $10.185 | $9.81 | $9.82 | 33.88K |
| Jul 31, 2026 | $10.05 | $10.4999 | $9.7201 | $10.08 | 26.9K |
| Jul 30, 2026 | $9.65 | $10.75 | $9.62 | $10.75 | 49.8K |
| Jul 29, 2026 | $12.83 | $12.83 | $12.01 | $12.01 | 3.48K |
| Jul 28, 2026 | $12.76 | $12.9826 | $12.3966 | $12.86 | 4.24K |
| Jul 27, 2026 | $12.85 | $13.02 | $12.85 | $13.013 | 5.74K |
| Jul 24, 2026 | $12.79 | $12.9592 | $12.57 | $12.615 | 5.37K |
The latest Smart Investors Daily articles mentioning PHAR.
PHAR research
Company profile and research snapshot.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 12, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| May 7, 2026 | OPPENHEIMER & CO., INC. | Outperform | — |
| Mar 29, 2026 | JEFFERIES | Buy | — |
| Feb 25, 2026 | FIRST BERLIN EQUITY RESEARCH | Buy | — |
| Feb 4, 2026 | OPPENHEIMER & CO., INC. | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 13, 2026
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwideOrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan
Yahoo · Aug 4, 2026
Leiden, the Netherlands, August 4, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levitan, VP Investor Relations and Capital Markets, will participate in a Fireside Chat Q&A session on Wednesday, August 12 at 10:00 EDT/16:00 CEST. For more information about the conference, or to schedule a one-on-one meeting with Pharming’s management team, please
Benzinga · Aug 3, 2026
Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $37 to $38.
Yahoo · Aug 3, 2026
Pharming Group guidance cut and half year results draw investor focus Pharming Group (ENXTAM:PHARM) has drawn fresh attention after lowering its 2026 revenue guidance by US$30 million and reporting half year 2026 results that showed reduced sales but a smaller net loss. See our latest analysis for Pharming Group. Pharming Group’s guidance cut and half year 2026 results appear to have fed into weaker sentiment, with the stock’s share price down 26.76% over 30 days and a 1 year total...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PHAR.
